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Abstract 
Background: Allergic conjunctivitis (AC) is usually associated to allergic rhinitis (AR), but the severity and control 
of ocular symptoms should be assessed independently to improve diagnosis and treatment. The criteria from the 
Spanish consensus document on allergic conjunctivitis (DECA) aimed to be used as a patient‑reported instrument for 
AC management. Here we validate these criteria for classifying AC severity and defining its control following COSMIN 
guidelines recommendations.
Methods: Patients with moderate or severe AR [reflective total nasal symptom score (rTNSS) score ≥ 8] and concomi‑
tant AC were recruited from hospitals in Spain. Patients were classified according to the severity of ocular symptoms 
as mild, moderate, or severe, and classified with respect to control as controlled and non‑controlled, using the DECA 
criteria. To validate these criteria, comparisons with the validated modified allergic rhinitis and its impact on asthma 
(mARIA), reflective total ocular symptom score (rTOSS), rhinitis control assessment test (RCAT), ESPRINT‑15 question‑
naires, a conjunctival hyperemia scale and a visual analogue scale (VAS) for ocular symptoms were performed.
Results: A total of 128 patients participated in the validation. Mean age was 34.4 ± 12.1 years; 72.7% were women. 
The DECA criteria showed a good discriminant validity, reflecting a high capacity to differentiate between mild, mod‑
erate, and severe patients, and controlled from uncontrolled patients. A strong association between AC and AR was 
reflected in the comparison between the DECA and the mARIA criteria (p < 0.0001). The DECA criteria for severity and 
control presented satisfactory properties for longitudinal validity and responsiveness.
Conclusions: Validation of the DECA criteria for severity and control of AC suggested that it can be useful in the 
evaluation of eye symptoms and follow‑up of therapies.
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Introduction
Allergic conjunctivitis (AC) is an immunological hyper-
sensitivity disorder of the ocular conjunctiva, predomi-
nantly mediated by an IgE mechanism [1]. AC occurs 
concomitantly with allergic rhinitis (AR) and other 
allergic disorders in most patients, but the ocular symp-
toms can be present without nasal involvement in 2–7% 
of AC patients [2, 3]. AC is a highly prevalent disease, 
affecting up to 40% of the adult population [1]. The most 
frequent symptoms are pruritus, tearing, and conjuncti-
val hyperemia. These symptoms can cause a significant 
impact on quality of life (QoL), affecting sleep and result-
ing in emotional problems and impairment of activities of 
daily living or social functions, such as work productivity 
or performance at school [4, 5]. AC is often underdiag-
nosed and undertreated, as only a small proportion of 
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[6]. Failure to recognize and treat ocular symptoms asso-
ciated with AR can increase the burden of the disease 
substantially for allergy patients.
To better understand disease progression and to help 
assessing the effectiveness of treatment pathways, in 
the last two decades the concepts of ‘disease severity’ 
and ‘disease control’ have been established for chronic 
allergic diseases [7]. Thus, several patient-reported out-
come (PRO) instruments have been developed to meas-
ure severity and control of AR [8, 9]. A successful and 
widely discussed initiative was the allergic rhinitis and 
its impact on asthma (ARIA) approach, which classified 
patients according to severity and, more recently, also to 
control [8, 10, 11]. The original ARIA document classi-
fied AR severity based on the impact of AR on 4 items: 
sleep, activities/leisure/sports, work productivity/school 
performance and bothersome symptoms [8]. Based on 
the original ARIA criteria, a severity classification for AC 
patients based on ocular symptoms was also proposed 
[12].
In 2015, experts from the Spanish Societies of Aller-
gology and Ophthalmology proposed a consensus of 
basic criteria that could be useful for both specialists 
and primary care physicians to facilitate the diagnosis, 
classification, control and treatment of patients with AC 
[13]. This consensus (henceforth named DECA, for its 
acronym in Spanish) was based on the modified ARIA 
(mARIA) classification of AR [14] adapted to AC (Fig. 1). 
The mARIA criteria classified patients as mild (when no 
items are affected), moderate (involvement of 1, 2 or 3 
items) and severe (involvement of the 4 items) in both 
untreated and treated patients [14, 15]. Accordingly, in 
the DECA classification three levels of severity were pro-
posed (mild, moderate, severe) and the criteria for fre-
quency were retained (intermittent/persistent).
The novel DECA criteria for control were based on the 
analysis of control criteria proposed for various allergic 
diseases [13]. AC was classified as controlled or uncon-
trolled based on 3 evaluation criteria: occurrence and 
frequency of ocular symptoms, a VAS score, and the 
degree of conjunctiva hyperemia as determined by the 
Efron scale [16].
The objective of this study was to validate the DECA 
criteria for classifying severity and control in AC patients, 
following the recommendations from the Consensus-
based Standards for the Selection of Health Measure-
ment Instruments (COSMIN) initiative [17], in a sample 
Fig. 1 The criteria from the Spanish consensus document on allergic conjunctivitis (DECA). a Criteria for severity; b Criteria for control
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of AC patients included in an observational study on the 
control of allergic rhinitis in Spain (CORINA) study.
Methods
This study was part of a larger observational, prospective, 
and multicenter real-life study to assess the epidemiol-
ogy of patients with moderate and severe AR in Spain 
in terms of control (CORINA), carried out between 
November 2015 and October 2016. Research was per-
formed by allergists and/or otorhinolaryngologists work-
ing at reference hospitals and health centers throughout 
Spain. To avoid a possible bias due to seasonality, each 
researcher included no more than 4 consecutive patients 
meeting the inclusion criteria each month until reach-
ing the target figure of 15 patients per investigator. The 
study was non-interventional as the clinical decision 
to prescribe treatments for the management of AC was 
made according to the usual clinical practice and was 
prior and independent of any consideration of the pos-
sible participation of patients in this study. During the 
study, patients received standard medical care without 
analytical tests or other clinical procedures specific to the 
study. All included patients had to sign informed consent 
and be able to attend the follow-up visit. The study was 
approved by the Ethics Committee for Clinical Research 
of the Hospital Clínic de Barcelona.
Patient population and study design
The inclusion criteria were age ≥ 18 years and a diagnosis 
of AC according to the criteria in the DECA document 
[13] (Fig.  1). All patients had moderate or severe AR 
according to mARIA criteria [14], with a reflective total 
nasal symptom score (rTNSS) of ≥ 8 (scale 0–12).
The patients made a first visit (baseline visit) and a 
second visit 4–5  weeks later (follow-up visit). We fol-
lowed COSMIN recommendations, as this international 
consensus established how to measure and evaluate in a 
uniform and consensual way the different health instru-
ments [17]. According to COSMIN, the DECA severity 
and control criteria were validated for:
1. Discriminant validity was evaluated by comparing 
differences in the reflective total ocular symptom score 
(rTOSS), the rTNSS, question 3 of the rhinitis control 
assessment test (RCAT), a visual analogue scale (VAS), 
hyperemia scale and question 4 from the ESPRINT-15 
questionnaire between patients classified in the differ-
ent categories of severity or control using DECA criteria. 
Also, the percentage of patients classified in each cat-
egory of severity using mARIA criteria was assessed for 
each category of AC severity by the DECA criteria.
2. Test–retest reliability was evaluated by analyzing 
the score agreement (kappa coefficient) in the basal and 
follow-up visits in those patients reporting equal AC 
severity or control. These patients were defined as those 
who had < 1.2 changes in the VAS score or ≤ 1 point in 
ESPRINT-15 question 4.
3. Responsiveness was assessed comparing the magni-
tude of the change in the different PROs (rTOSS, VAS, 
the Efron scale, and ESPRINT-15 question 4 for severity 
and rTOSS, ESPRINT-15 question 4, and RCAT question 
3 for control) for three options of change in severity and 
control: worse, equal and improved.
Patient‑reported outcomes and assessments
The values of all the study variables were extracted from 
the patients’ medical records and from the study ques-
tionnaires filled out during the visits. Data was collected 
on demography, concomitant diseases and medication 
use, etiology of allergic sensitization, and severity and 
control of AC.
AC symptoms evaluated were pruritus, tearing and 
redness. Each of the symptoms was evaluated on a scale 
between 0 (no symptom) and 3 (severe symptom) and 
on a VAS (0–10  cm; 0 = no symptoms, 10 = maximum 
severity). Conjunctive hyperemia was measured with 
the grading scale by Efron (0–4; 0 = normal, 4 = severe) 
[16]. The rTOSS was calculated as the sum to the indi-
vidual score at 3 symptoms, with a maximum score of 9. 
Question 3 of the Spanish-validated RCAT was used to 
evaluate control: “During the past week, how often did 
you have watery eyes?” (5–1; 5 = never, 1 = extremely 
often) [18, 19]. Question 4 of the Spanish version of the 
ESPRINT-15 questionnaire was used to evaluate affec-
tation of quality of life: “In the past 2 weeks, how much 
have you been bothered by itchy eyes or having to rub 
your eyes?” (0–6; 0 = not at all; 6 = extremely) [20, 21].
AC severity was classified according to the DECA cri-
teria based on the impact on 4 items: bothersome symp-
toms, affectation of vision, interference with academic 
or work tasks, or interference with daily activities, read-
ing and/or sport (Fig.  1a) [13]. Based on these criteria, 
patients were classified as mild (no items affected), mod-
erate (involvement of 1, 2 or 3 items) and severe (involve-
ment of the 4 items). AC was also classified according to 
its duration in intermittent (up to 4 days/week or up to 4 
consecutive weeks) or persistent (more than 4 days/week 
and more than 4 consecutive weeks).
The degree of AC control was assessed, according to the 
DECA criteria, by symptoms, VAS and the Efron scale for 
conjunctival hyperemia (Fig.  1b) [13]. AC was consid-
ered controlled if there were no symptoms or they were 
not bothersome 2 or more days per week, VAS < 5  cm 
and hyperemia scale was 0–1. It was considered uncon-
trolled if at least one of the following items was observed: 
symptoms with any intensity 2 or more days per week, 
VAS ≥ 5 cm and/or hyperemia scale was 2–4.
Page 4 of 9Sánchez‑Hernández et al. Clin Transl Allergy           (2020) 10:43 
Statistical methods
For the statistical analysis, the package SAS version 
9.2 for Windows was used. The mean, median, stand-
ard deviation, minimum and maximum, 25th and 75th 
percentiles, and the number of valid cases were used 
for the description of continuous variables. The num-
ber and percentage of patients per response category 
was used for categorical variables. Prior to performing 
parametric tests, we applied statistical techniques to 
ensure compliance with the assumptions. In case the 
established assumptions were not met, non-parametric 
tests were employed. A level of statistical significance 
(p-value) of < 0.05 was used for all statistical tests.
Results
The CORINA study recruited 252 patients [18]. Of 
these, 198 (78.6%) presented with AC symptoms in 
the basal visit, and 128 patients (50.8%) in the follow-
up visit. The validation of the DECA criteria for sever-
ity and control was performed on this sample of 128 
patients with AC symptoms and who attended both 
the baseline and the follow-up visits. Table  1 shows 
the baseline characteristics of the patients included 
in this study. The mean age of the AC patients was 
34.4 ± 12.1  years and 72.7% were women. The mean 
time elapsed between the date of diagnosis and the 
study was 6.3 ± 9.7  years. At the basal visit, 94.5% of 
patients presented pruritus, 85.9% tearing, and 85.9% 
redness. All patients presented moderate or severe 
AR (100%) and 41.4% had concomitant asthma, 10.9% 
atopic dermatitis, and 3.1% food allergy. The most fre-
quent allergen sensitizations were to dust mites (57.7%) 
and grass pollens (45.5%), while 63% of the patients 
presented polysensitization. Regarding type of AC sen-
sitization, for 25.2% of the patients it was seasonal, for 
32.5% perennial, and for 42.3% both. Table 1 shows the 
treatment followed by the patients at baseline, which 
the specialist adjusted according to current guidelines 
at baseline, modifying it in 63.3% of cases and initiating 
it in 20.3%.
Validation of the DECA criteria for AC severity
Discriminant validity
Table 2 shows the scores of the different validated PROs 
when assessed according to the severity categories 
defined by using the DECA criteria. A highly significant 
discriminant validity of the DECA criteria for severity 
was found when comparing these scores. The percent-
age of patients classify similarly regarding severity with 
the mARIA criteria and the DECA criteria also showed a 
good balance facing both systems (Fig. 2).
Table 1 Baseline characteristics of  the  patients included 
in the DECA criteria for AC severity and control validation 
study (N = 128)
Age, years, mean (SD) 34.4 (12.1)
Gender, female, N (%) 93 (72.7)
Allergic comorbidities, N (%)
 AR 128 (100.0)
 Asthma 53 (41.4)
 Atopic dermatitis 14 (10.9)
 Urticaria 11 (8.6)
 Contact dermatitis 4 (3.1)
 Food allergy 4 (3.1)
 Other 14 (10.9)
Type of AC sensitization, N (%)
 Perennial 40 (32.5)
 Seasonal 31 (25.2)
 Both 52 (42.3)
rTOSS score, mean (SD) 5.4 (2.3)
Hyperemia (Efron scale), N (%)
 Normal 26 (20.3)
 Trace 62 (48.4)
 Mild 29 (22.7)
 Moderate 11 (8.6)
AC duration, N (%)
 Intermittent 44 (34.4)
 Persistent 84 (65.6)
Items reported (DECA), N (%)
 Bothersome symptoms 116 (90.6)
 Affecting vision 39 (30.5)
 Interference with academic or work tasks 54 (42.2)
 Interference with daily activity, reading, sport 66 (51.6)
Severity (DECA criteria), N (%)
 Mild (no items affected) 10 (7.8)
 Moderate (1–3 items affected) 93 (72.7)
 Severe (4 items affected) 25 (19.5)
Control (DECA criteria), N (%)
 Controlled 27 (21.1)
 Not controlled 101 (78.9)
Ophthalmic treatments at baseline, N (%)
 Azelastine 34 (26.6)
 Ketotifen 11 (8.6)
 Olopatadine 3 (2.3)
 Levocabastine 1 (0.8)
 Others 1 (0.8)
Nasal treatments at baseline, N (%)
 Budesonide 2 (1.6)
 Fluticasone 12 (9.4)
 Mometasone 22 (17.2)
 Triamcinolone 1 (0.8)
 Fluticasone furoate 43 (33.6)
 Fluticasone/azelastine combination 41 (32.0)
AC: allergic conjunctivitis; AR: allergic rhinitis; DECA: Spanish document on 
allergic conjunctivitis; rTOSS: reflective total ocular symptom score; SD: standard 
deviation
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Test–retest reliability
Thirty-three patients had the same AC severity as assessed 
by the VAS, resulting in a kappa value of 0.45 (72.7% agree-
ment) with the DECA severity criteria, and 56 patients for 
the ESPRINT-15 question 4, kappa value of 0.33 (62.5% 
agreement), reflecting a fair test–retest reliability.
Responsiveness
The magnitudes of the change in the PROs scores for 
patients who worsened, improved or stayed the same 
in their AC severity were significantly different regard-
ing rTOSS, VAS, the Efron hyperemia scale, and 
ESPRINT-15 question 4 (Fig.  3a), suggesting that the 
Table 2 Mean (standard deviation) for  the  scores of  the  different validated patient reported outcomes assessed 
in the severity categories classified by using the DECA criteria
DECA: Spanish document on allergic conjunctivitis; ESPRINT‑15: Spanish allergic rhinitis quality of life questionnaire; rTOSS: reflective total ocular symptom score; VAS: 
visual analogue scale; SD: standard deviation
*ESPRINT‑15 Question 4: “In the past 2 weeks, how much have you been bothered by itchy eyes or having to rub your eyes?”
DECA criteria p
Mild Moderate Severe
Ocular symptoms (0–3), mean (SD)
 Pruritus 0.77 (0.83) 1.61 (0.84) 1.89 (1.05) < 0.0001
 Tearing 0.47 (0.78) 1.25 (0.89) 1.78 (1.09) < 0.0001
 Redness 0.43 (0.68) 1.28 (1.01) 1.78 (0.83) < 0.0001
rTOSS score (0–9), mean (SD) 1.66 (1.98) 4.17 (2.28) 5.44 (2.65) < 0.0001
Ocular symptoms by VAS (0–10 cm), mean (SD)
 Pruritus 1.70 (2.17) 4.48 (2.94) 5.30 (2.86) < 0.0001
 Tearing 1.45 (2.30) 3.80 (2.95) 4.79 (3.20) < 0.0001
 Redness 1.35 (2.41) 3.94 (3.05) 4.56 (3.03) < 0.0001
VAS global score 1.82 (2.21) 4.87 (2.88) 6.14 (3.01) < 0.0001
Efron hyperemia scale (0–4), mean (SD) 0.10 (0.31) 0.93 (0.81) 1.20 (1.14) < 0.0001
ESPRINT‑15 (0–6), mean (SD)
 Question 4*
1.39 (1.51) 3.32 (1.71) 4.10 (1.37) < 0.0001
Fig. 2 Percentage of patients in each allergic conjunctivitis (AC) severity category using DECA criteria (mild, moderate, or severe) and for each 
allergic rhinitis (AR) severity category by mARIA
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DECA criteria for severity showed good responsiveness 
to detect changes on symptoms, ocular signs and quality 
of life.
Validation of the DECA criteria for AC control
Patients classified as controlled by the DECA criteria 
showed PROs scores significantly different from patients 
classified as uncontrolled, indicating a high discriminant 
validity of the DECA criteria for AC control (Table 3).
Patients who did not report changes in AC control, 
when assessed by DECA criteria, between the basal and 
follow-up visits (N = 15) showed a similar score in PROs 
(Kappa value of 0.59; 80% agreement), proving a good 
test–retest validity.
The changes in PROs scores for patients who changed 
their level of control assessed by DECA criteria were sig-
nificantly and relevantly higher than patients who do not, 
showing a good responsiveness (Fig. 3b).
Discussion
This study successfully validated the DECA criteria for 
severity and control of AC according to the require-
ments established in the COSMIN: discriminant validity, 
test–retest reliability, and responsiveness [17]. The data 
obtained in the CORINA study described here suggest 
that the DECA criteria could be used to rapidly assess AC 
severity and control of the disease in patients with AC 
symptoms.
Despite the increase in allergic eye diseases in recent 
decades and the socioeconomic impact generated by AC 
[3–5, 22], it is commonly accepted that AC is often under-
diagnosed and undertreated [6]. This could be due in part 
to the highly frequent comorbidity of AC with other more 
severe allergic diseases such as asthma [23]. In our study 
we also observed this frequent comorbidity, as asthma 
was present in 41.4% of the patients and atopic dermatitis 
in 10.9% (in addition to rhinitis which, for methodologi-
cal reasons, was present in all patients). Another possible 
reason for the underdiagnosis of AC could be the lack of 
an unanimously agreed classification criteria. Addition-
ally, in most epidemiological studies on allergic diseases 
the eye and nasal symptoms have been treated as a single 
clinical entity [24]. For these reasons, in an effort to bring 
together the classification criteria of AC and AR and to 
unify nomenclature on AC, the DECA consensus docu-
ment proposed a new classification of AC and also added a 
proposal for the definition of AC control [13].
In this study some relevant properties of the DECA cri-
teria were assessed. The discriminant validity for disease 
severity, as shown in Table  2, reflected a high capacity 
to differentiate mild, moderate, and severe patients. The 
extent by which AC is associated with AR could also be 
observed when patient classification by the DECA criteria 
were compared with the mARIA criteria. Although AR 
severity and AC severity do not necessarily have to fol-
low parallel classifications, in our study we observe a 
good agreement between the two, suggesting that these 
instruments are effective and can simplify and expedite 
the classification of both diseases [25]. Additionally, we 
find it is highly useful to differentiate AC severity in three 
categories (mild, moderate, and severe), as differentiating 
moderate to severe patients can reduce the heterogeneity 
in the higher severity status [14, 15].
The capacity of the DECA criteria to discriminate 
patients according to the degree of AC control can be 
observed in Table 3, clearly suggesting their validity. Lon-
gitudinal validity and responsiveness for the DECA crite-
ria severity and control were also acceptable and suggest 
that they could be useful in the evaluation and follow-up 
of treated patients.
This validation study had some limitations. First, it only 
included patients with a diagnosis of moderate to severe 
AR or that patients with ocular symptoms alone were not 
included. Second, a methodological limitation derives 
from the lack of a standard and normalized classification 
for eye symptoms related to AC. For this reason, in our 
validation we could only compare the DECA criteria with 
other validated instruments previously applied to various 
aspects of symptom severity and quality of life formally 
designed for AR. We have also used the specific ocu-
lar items of the ESPRINT-15 and RCAT questionnaires 
(questions 4 and 3, respectively), but these items were not 
designed to be used in isolation and therefore their reli-
ability has not been validated. Similarly, comparison with 
other classification schemes previously proposed before 
has not been possible, as they have not been validated.
One of the strengths of this study is that it showed for 
the first time the validation of an instrument specific for 
AC control, following the COSMIN recommendations 
for reliability, validity and responsiveness [17]. It has been 
suggested that measurements of disease control should 
be reproducible and easily implementable in everyday 
practice and focused on the disease’s impact in daily life 
[9]. In this regard, the DECA criteria are designed to be 
a practical tool used by primary health practitioners and 
specialists alike. Further, the proposed clinical classifi-
cation of AC severity is consistent and complementary 
with that currently in use for AR severity. The unifica-
tion of criteria for the evaluation of severity and con-
trol is important in the development of diagnostic and 
treatment guidelines for common use by primary care 
physicians, allergists, and ophthalmologists, as a mul-
tidisciplinary communication is necessary for the opti-
mal management of AC patients [1, 6, 9]. In this regard, 
the validated instruments described here could also be 
used to rapidly screen these patients with AC control 
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problems and could help patients to communicate with 
health care practitioners about their disease and their 
response to treatment.
Conclusion
This study validated with good results the criteria for 
severity and control assessment proposed in DECA, 
making this a potentially useful tool for physicians and 
Fig. 3 Boxplots showing the DECA criteria score changes (median, 25th and 75th interquartile values) between visits for AC patients, which 
were categorized as worse, equal, or improved compared to baseline. a Comparisons for PROs evaluating severity. The differences are statistically 
significant for rTOSS (p < 0.0001), VAS (p < 0.0001), hyperemia scale (p < 0.0002), and ESPRINT‑15 question 4 (p < 0.0001). b Comparisons for PROs 
evaluating control. The differences were statistically significant for rTOSS (p < 0.0001), ESPRINT‑15 question 4 (p < 0.0001), and RCAT question 3 
(p < 0.0002)
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patients in the evaluation of eye symptoms and follow-up 
of therapies.
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Table 3 Mean (standard deviation) of  the  different 
validated patient reported outcomes for  controlled 
versus  not  controlled AC control assessed by  the  DECA 
criteria
DECA: Spanish document on allergic conjunctivitis; ESPRINT‑15: Spanish allergic 
rhinitis quality of life questionnaire; RCAT: rhinitis control assessment test; rTOSS: 
reflective total ocular symptom score; VAS: visual analogue scale
* ESPRINT‑15 Question 4: “In the past 2 weeks, how much have you been 
bothered by itchy eyes or having to rub your eyes?”




Ocular symptoms (0–3), mean (SD)
 Pruritus 0.94 (0.86) 2.00 (0.71) < 0.0001
 Tearing 0.65 (0.89) 1.62 (0.82) < 0.0001
 Redness 0.60 (0.81) 1.76 (0.99) < 0.0001
rTOSS score (0–9), mean (SD) 2.19 (2.25) 5.38 (1.97) < 0.0001
Ocular symptoms by VAS (0–10 cm), mean (SD)
 Pruritus 0.94 (0.86) 2.00 (0.71) < 0.0001
 Tearing 0.65 (0.89) 1.62 (0.82) < 0.0001
 Redness 0.60 (0.81) 1.76 (0.99) < 0.0001
ESPRINT‑15 (0–6), mean (SD)
 Question 4*
1.75 (1.60) 4.33 (1.40) < 0.0001
RCAT (5‑1), mean (SD)
 Question 3**
3.68 (1.13) 2.20 (0.96) < 0.0001
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